The Mayo Clinic has launched CANCP, a 50-gene cancer panel that assesses hotspot mutations using next-generation sequencing with the goal of predicting a patient's response to therapy. The test is available to Mayo patients and providers worldwide through Mayo Medical Laboratories.
Oxford Gene Technology has launched SureSeq Solid Tumor Panel, a 60-gene cancer panel that uses hybridization-based enrichment and is assessed via next-generation sequencing. The panel was validated on formalin-fixed paraffin embedded tissue and covers the entire exons of the 60 genes.
Natera has received conditional approval from the New York State Department of Health to use its next-generation sequencing-based, noninvasive prenatal test, Panorma, to test for chromosomal aneuploidies and DiGeorge syndrome in all pregnant women.